Genenta Science (Evolving into Saentra Forge) Announces Binding Offer to Acquire Controlling Stake in Sòphia High Tech

GNTA
March 27, 2026

Genenta Science S.p.A., which is in the process of becoming Saentra Forge, entered into a binding offer on March 25 2026 to acquire a controlling stake in Sòphia High Tech S.r.l., an Italian aerospace and defense engineering firm headquartered in Somma Vesuviana.

The deal will see Genenta provide €6 million in capital through two reserved capital increases. An initial tranche will secure a 30 % equity position, while a second tranche, contingent on meeting EBITDA milestones, will be paid as a performance‑based earn‑out. The transaction is subject to confirmatory due diligence, regulatory approvals, and definitive documentation.

Strategically, the acquisition marks a pivot for Genenta from its original Temferon gene‑therapy platform toward becoming an industrial consolidator in sectors deemed critical to national security. By adding Sòphia’s proven manufacturing capabilities—certified to EN9100 and capable of 3D‑printing flight‑ready hardware for ESA and NASA—Genenta aims to diversify its portfolio and leverage the company’s strong client base, including the European Space Agency, Leonardo, and MBDA.

Management highlighted the synergy and strategic fit. CEO Pierluigi Paracchi said, "Our decision to pursue the acquisition of Sòphia High Tech was not driven simply by the fact that it is a great company — though it is. We are proposing to acquire it because it represents exactly the kind of irreplaceable industrial asset that Italy cannot afford to lose." CEO Antonio Caraviello added, "A strong synergy was immediately established with Genenta. Through investments focused on facilities, certifications, and people, it will ensure, in addition to an increase in Sòphia’s manufacturing activities, an ever‑increasing involvement with our customers."

The binding offer follows Genenta’s earlier agreement to acquire ATC, a tactical‑rifle manufacturer, underscoring the company’s broader strategy to consolidate specialized Italian firms in strategic sectors such as biotechnology, cybersecurity, and defense. This move aligns with Italy’s Golden Power legislation, which facilitates foreign investment in national‑security‑related businesses.

The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.